AI Trading Robot,Swing trader: Long-Short Equity Strategy (TA&FA), Boosts BIIB by 4.47% in a Week

Novartis AG's remarkable 20.34% increase in share price this month can be attributed to the positive trends in the pharmaceutical industry and the company's strong earning results.

Johnson & Johnson (JNJ) is expected to see a significant increase in price in the next year, with a median target of 178.10 by analysts. This comes after JNJ was one of the top gainers this week, climbing +8.02% to $165.61 per share. A.I.dvisor's analysis also shows that the Pharmaceuticals: Major Industry is on an upward trend, with 88.24% of the 57 stocks analyzed trending up.

Discover why Organon & Co (OGN) has been a top loser in the Pharmaceuticals: Major Industry over the last three months, falling -25.36%. Find out how the Momentum Indicator for OGN has recently turned positive, indicating a new upward trend, and the potential opportunities it may present for traders.

Today, there are several important reports scheduled for release that could impact the market. I see these upcoming releases as an opportunity for growth in the American stock market, and our robots are currently prioritizing long positions. If I had to choose a robot for this week, I would select the Swing Trader Popular Stocks 4K per position Market Neutral Strategy, which can almost always be found in market-neutral positions and tends to generate the highest profit in any market condition.

Pfizer Inc. shares fell Tuesday, after the drugmaker posted fourth quarter earnings that surpassed analysts’ expectations while issuing a softer 2023 growth guidance amidst cooling off of its Covid treatments’ sales. Pfizer’s adjusted earnings for the three months ending in December came in at $1.14 per share, beating the Street consensus forecast of $1.05 per share. Revenues climbed +2%...

The U.S. Food and Drug Administration approved the Alzheimer's drug lecanemab developed by Eisai Co Ltd and Biogen Inc for patients in the earliest stages. Eisai had applied for full FDA approval of the drug. The drugs aims to slow the advance of the disease by removing sticky clumps of the toxic protein beta amyloid from the brain. “Today’s news is incredibly important," said Dr. Howard...

Biogen shares plunged on Monday, following reports that a woman who participated in a trial of the drugmaker's developing Alzheimer's treatment died due to a brain hemorrhage. The company is developing the drug with Eisai Co. According to Science.org, the case involved a 65-year-old woman who died of a massive brain hemorrhage following a stroke and a type of brain swelling and bleeding in a...

AbbVie Inc. ‘s third quarter earnings came in at $3.66 per share for the third quarter of 2022 (up +29.3% from the year-ago quarter), exceeding the Zacks Consensus Estimate of $3.56 per share. Revenues rose +3.3% year-over-year to $14.81 billion, missing the Zacks Consensus Estimate of $14.92 billion. In immunology, AbbVie’s flagship drug Humira experienced a 3.9% sales growth to $5.56...

Johnson & Johnson reported third quarter earnings that topped the Street expectations. The company also boosted its full-year profit outlook, as strength in pharmaceuticals sales offset a decrease in Covid vaccine revenues. Johnson & Johnson’s adjusted earnings for the three months ending in September fell -1.9% year-over-year to $2.55 per share, but exceeded analysts’ expectations by 7...

Pfizer Inc has submitted a application to the FDA for the approval of Paxlovid, which is intended to treat patients at high risk for progression to severe illness from COVID-19. Currently, Paxlovid is authorized for emergency use for mild-to-moderate COVID-19 in adults and pediatric patients at high risk for progression to severe COVID-19. The submission includes non-clinical and clinical...

Pfizer Inc. reported its fourth quarter earnings that surpassed expectations. The biotech company’s adjusted earnings for the three months ending in December surged +157% from the year-ago quarter to $1.08 per share, beating the Street consensus forecast of 87 cents. Revenues rose +104% year-over-year to $23.8 billion, compared to analysts' estimates of $24.1 billion. Looking ahead, Pfizer...

Pfizer Inc. and BioNTech got approval from The Food and Drug Administration (FDA) for authorizing Covid booster shots in children aged 12 to 15. This is an emergency use authorization, amid omicron variant spread. The FDA also narrowed the time for administration of a booster dose from at least six months to at least five months following completion of the primary series for people 12 and...

Biogen shares took a hit, after Samsung BioLogics denied a report that claimed that it's discussing takeover plans that at a value of around $42 billon. Korea Economic Daily report mentioned ties between the two groups including FDA approval of key treatments, as well as Biogen's 50% stake minus one share in biosimilars unit Samsung Bioepis Co. The report also stated plans from the Samsung...

Pfizer said final analysis of its antiviral Covid-19 pill reveals almost 90% efficacy in preventing hospitalizations and deaths among high-risk patients. In a final study data, Pfizer said its Paxlovid treatment remained 89% effective in preventing hospitalizations in high-risk unvaccinated people when used within three days of the appearance of symptoms. However, a separate study suggested...

Bristol-Myers Squibb increased its quarterly dividend and added $15 billion to its buyback program. The pharmaceutical company’s third quarter earnings came in at $2 per share. It boosted its dividend by 10.2%, to 54 cents per share, while taking its total share buyback program to $15.2 billion. The company now expects its fiscal 2022 dividend to rise to $2.16 per share, which would be the...

Pfizer and partner BioNTech are going to seek the approval of the U.S. Food and Drug Administration possibly this week to expand Covid-19 booster shot eligibility to 16- and 17-year-olds. Currently, 18 and older are eligible for booster shots six months after receiving the second shot of the Pfizer-BioNTech or Moderna vaccine. According to the Washington Post, the regulators are expected to...

Pfizer Inc. and partner BioNTech said that a trial of their Covid vaccine booster was 95.6% effective. According to the biotech companies, the results were based on a Phase 3 randomized, controlled trial evaluating the efficacy and safety of a 30-µg booster dose of the Pfizer-BioNTech Covid-19 vaccine in more than 10,000 individuals 16 years of age and older. “In the trial, a booster dose...

Pfizer Inc. said that results from its Covid-19 vaccine’s late-stage trial involving young children showed a "favorable safety profile and robust neutralizing antibody responses." The pharmaceutical company said that a 10 µg dose given to children between the ages of 5 and 11 (which is around a third of that given to older children and young adults in similar testing) produced comparable...

Gilead Sciences’ quarterly adjusted earnings came in at $1.87 per share for the quarter ended June, surpassing Zacks Consensus Estimate of $1.76 per share.It was $1.11 per share in the year-ago quarter.

The biopharma company has exceeded consensus EPS estimates four times over the last four quarters.

Gilead’s revenues were $6.22 billion, beating the Zacks Consensus Estimate by 1.14%.